Similar articles for PMID: 17961213

Year	Number of Results
2001	1
2002	2
2003	20
2004	22
2005	10
2006	11
2007	13
2008	7
2009	5
2010	7
2011	2
2014	1
2016	1
2020	1
2024	0

1

HIV-1 drug-resistance and drug-dependence.

Baldwin C, Berkhout B. Baldwin C, et al. Retrovirology. 2007 Oct 25;4:78. doi: 10.1186/1742-4690-4-78. Retrovirology. 2007. PMID: 17961213 Free PMC article. Review.

2

Virological fitness of HIV in patients with resistance to enfuvirtide.

Chibo D, Roth N, Roulet V, Skrabal K, Gooey M, Carolan L, Nicholls J, Papadakis A, Birch C. Chibo D, et al. AIDS. 2007 Sep 12;21(14):1974-7. doi: 10.1097/QAD.0b013e3282ef1bc8. AIDS. 2007. PMID: 17721108

3

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.

Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR. Deeks SG, et al. J Infect Dis. 2007 Feb 1;195(3):387-91. doi: 10.1086/510531. Epub 2006 Dec 21. J Infect Dis. 2007. PMID: 17205477 Clinical Trial.

4

Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.

Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M. Menzo S, et al. New Microbiol. 2004 Apr;27(2 Suppl 1):51-61. New Microbiol. 2004. PMID: 15646065

5

Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?

Morse C, Maldarelli F. Morse C, et al. J Infect Dis. 2007 Feb 1;195(3):318-21. doi: 10.1086/510539. Epub 2006 Dec 21. J Infect Dis. 2007. PMID: 17205468 Review. No abstract available.

6

Enfuvirtide approved for defusing HIV.

Burton A. Burton A. Lancet Infect Dis. 2003 May;3(5):260. doi: 10.1016/s1473-3099(03)00620-0. Lancet Infect Dis. 2003. PMID: 12726955 No abstract available.

7

Enfuvirtide for prophylaxis against HIV Infection.

Ferranti S, Menichetti F. Ferranti S, et al. N Engl J Med. 2003 Aug 21;349(8):815. doi: 10.1056/NEJM200308213490820. N Engl J Med. 2003. PMID: 12930939 No abstract available.

8

Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.

Poveda E, Briz V, Paraskevis D, Barreiro P, Hatzakis A, Soriano V. Poveda E, et al. AIDS Res Hum Retroviruses. 2007 Sep;23(9):1078-82. doi: 10.1089/aid.2006.0287. AIDS Res Hum Retroviruses. 2007. PMID: 17919101

9

Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.

Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M. Menzo S, et al. Antimicrob Agents Chemother. 2004 Sep;48(9):3253-9. doi: 10.1128/AAC.48.9.3253-3259.2004. Antimicrob Agents Chemother. 2004. PMID: 15328081 Free PMC article.

10

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group. Lalezari JP, et al. N Engl J Med. 2003 May 29;348(22):2175-85. doi: 10.1056/NEJMoa035026. Epub 2003 Mar 13. N Engl J Med. 2003. PMID: 12637625 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

98 results

Results by year